Abstract
Abstract Background: Several trials have reported on eosinophilia in cancer patients receiving immunotherapy therapy of cancer especially checkpoint inhibitors. There is limited reports on eosinophilia and immunotherapy in triple-negative breast cancer (TNBC). Patients: We are reporting on eosinophilia and the increase in eosinophil count in a trial testing the combination of Durvalumab band paclitaxel in metastatic TNBC NCT02628132. In this trial 19 patients were recruited, however, only 14 received the combination therapy while the 5 drop out due to progression on paclitaxel alone priming cycle. Results: One of the patients developed eosinophilia after having a complete response status. The developed eosinophilia lasted for a year and subsided with temporary holding treatment. Among all patients enrolled who received the combination therapy, there was a statistically significant correlation between an increase in eosinophil count (>300/mm3) during treatment and a having partial or complete response to the combination therapy (p 0.028). In agreement, survival analysis showed a significant association between disease-free survival (DFS) and higher PCE count (p 0.005). A similar trend existed with overall survival (OS), although it did not reach significance (p 0.167). The increase in eosinophil count correlated significantly with skin rash/pruritus (p 0.028). On the other hand, the association between baseline PEC before treatment and response to treatment was not statistically significant despite the positive trend. Conclusions: An increase in circulating eosinophil count correlates with response to therapy with chemo-immunotherapy combination in metastatic TNBC. This study supports the role eosinophils are playing in the treatment of cancer. Citation Format: Hazem Ghebeh, Mahmoud A. Elshenawy, Adher Al-Sayed, Taher Al-Tweigeri. An increase in eosinophils is associate with response to chemo-immunotherapy in metastatic triple negative breast cancer [abstract]. In: Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; 2021 Oct 5-6. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(1 Suppl):Abstract nr P059.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
